Cargando…

The role of surgery following incomplete response to high-dose IL-2 (HD IL-2)

Detalles Bibliográficos
Autores principales:	Hughes, Tasha, Iodice, Gail, Basu, Sanjib, Bines, Steven, Kaufman, Howard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991359/ http://dx.doi.org/10.1186/2051-1426-1-S1-P145

Ejemplares similares

Clinical benefit of high dose IL-2 (HD IL-2) therapy: evidence for improved overall survival in patients with stable disease
por: Hughes, Tasha, et al.
Publicado: (2013)

Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2
por: Kaufman, Howard L, et al.
Publicado: (2014)

Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)
por: Clark, Joseph I, et al.
Publicado: (2015)

Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2
por: Wong, Michael KK, et al.
Publicado: (2015)

Complete metastasectomy after high-dose interleukin-2 (HD IL-2) therapy for melanoma
por: Chu, Melinda, et al.
Publicado: (2015)

Role of dose selection in successful interleukin-2 immunotherapy: solving the Goldilock’s Complex
por: Zloza, Andrew, et al.
Publicado: (2013)

High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates
por: Wong, Michael K, et al.
Publicado: (2013)

Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin(® )(HD IL-2) and Ipilimumab Yervoy(® )) in patients with metastatic melanoma (proclivity 02)
por: Patel, Sapna, et al.
Publicado: (2014)

High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection
por: Chow, Shien, et al.
Publicado: (2014)

A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (proclivity 01)
por: Clark, Joseph, et al.
Publicado: (2014)

IL-2, IL-15 and IL-21 expand T cells for targeted adoptive therapy
por: Liu, Zhenjiang, et al.
Publicado: (2015)

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
por: Buchbinder, Elizabeth I., et al.
Publicado: (2016)

Associations of Fc gamma receptor (FcgR2a, FcgR3a and FcgR2c) genotype with outcome in metastatic renal cell carcinoma (mRCC) patients receiving high dose interleukin 2 (HD-IL2)
por: Erbe, Amy K, et al.
Publicado: (2015)

P16-30. Induction of Tim-3 expression by the common gamma-chain cytokines IL-2, IL-7, IL-15 and IL-21
por: Jones, BR, et al.
Publicado: (2009)

Adoptive cell therapy with tumor infiltrating lymphocytes and intermediate dose IL-2 for metastatic melanoma
por: Andersen, Rikke, et al.
Publicado: (2014)

Selective costimulation by IL-15R/IL-15, but not IL-2R/IL-2, allows the induction of high numbers of tumor-specific CD8+ T cells by human dendritic cells matured in conditions of acute inflammation
por: Hansen, Morten, et al.
Publicado: (2015)

Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival
por: Broucek, Joseph R, et al.
Publicado: (2013)

IL-2 analogues: novel agents circumventing the expansion of T regulatory cells while promoting NK cell activation during IL-2 therapy
por: Sim, Geok Choo, et al.
Publicado: (2013)

The Th2 cytokines IL-4 and IL-10 are internal controllers of human Th1-biased immunity in vivo
por: Skapenko, A, et al.
Publicado: (2003)

Intracellular IL-1 receptor antagonist (icIL-1Ra1) does not antagonize growth inhibitory effects of pre-IL-1α in SaOS-2 cells
por: Palmer, G, et al.
Publicado: (2005)

Measurement of granulocyte colony-stimulating factor and IL-6, IL-8 and IL-10 as an early predictor for septic patients
por: Razek, A Abdel, et al.
Publicado: (2005)

Feasibility of dc vaccine combined with low dose endoxan and high dose il-2 treatment associated with taurolidine for advanced, multi-resistant melanoma patients.
por: Moviglia, Gustavo A, et al.
Publicado: (2015)

The role of synovial fluid cytokines IL-6, IL-23 and IL-17 in the pathogenesis and persistence of synovial inflammation in JIA patients
por: Tzimouli, V, et al.
Publicado: (2008)

Bystander memory CD8 T cell proliferation after anti-CD40/IL-2 treatment is independent of CD4 T cells
por: Grossenbacher, Steven K, et al.
Publicado: (2013)

Pathogenic roles of IL-6 and IL-6 blocking therapy on rheumatoid arthritis
por: Yoshizaki, K, et al.
Publicado: (2003)

Dose effects of recombinant human IL-11 on the systemic hemodynamic function in hemorrhagic shock
por: Honma, K, et al.
Publicado: (2007)

Plasma levels of IL-6 and IL-10 in septic patients at admission and during follow-up and association with clinical outcomes
por: Costa, RT, et al.
Publicado: (2011)

Combination immunotherapy with anti-CTLA-4 and interleukin-2 redirects regulatory T cells into tumor-draining lymph nodes and expands anti-tumor CD8+ T cells in the tumor microenvironment
por: Broucek, Joseph, et al.
Publicado: (2014)

A high IL6/IL17 ratio combined with low IL5 expression is correlated with poor survival in squamous cervical cancer
por: Punt, Simone, et al.
Publicado: (2014)

IL-1 but not IL-18 induces osteoprotegerin and TRAIL in rheumatoid arthritis synovial fibroblasts
por: Morel, J, et al.
Publicado: (2003)

Electrotransfer of IL-15/IL-15Rα complex for the treatment of established melanoma
por: Shirley, Shawna, et al.
Publicado: (2015)

Kaposi sarcoma herpesvirus (KSHV)-associated lymphomas are associated with markedly elevated serum IL-10, elevated IL-6, IL-17 and circulating KSHV
por: Uldrick, Thomas S, et al.
Publicado: (2012)

IL-1 receptor antagonist restores IL-18 NK cell axis in systemic JIA
por: Vastert, Sebastiaan J, et al.
Publicado: (2012)

High-dose IL-2 in metastatic melanoma: better survival in patients who also received patient-specific autologous tumor cell vaccine
por: Dillman, Robert O, et al.
Publicado: (2013)

Improving adoptive T cell therapy with adenoviruse armed with TNF-α and IL-2
por: Havunen, Riikka, et al.
Publicado: (2015)

Mobilization permits reliable ELISPOT detection of long-term memory T cells secreting IFN-γ, IL-4, IL-5, and IL-17 without in vitro expansion
por: Ghosh, Jaya, et al.
Publicado: (2013)

Monitoring of procalcitonin, IL-6 and brain natriuretic peptide for sepsis diagnosis in cardiac surgery
por: Barchetta, R, et al.
Publicado: (2009)

Dose-dependent effects of octreotide on plasma activities of IL-6 and lung tissue levels of malondialdehyde in sepsis
por: Gul, M, et al.
Publicado: (2007)

PD36 - Evaluation of intracellular cytokines IL-2, IFNγ, IL-4 and IL-5 in children with atopic dermatitis and correlations with other immunological and epidemiological parameters
por: Koulouri, Maria, et al.
Publicado: (2014)

What's new in IL-12? Combination!
por: Lawrence, Chris E, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_do9mctepk547bpt06jtipeobm9